ASMB Stock Analysis: Buy, Sell, or Hold?
ASMB - Assembly Biosciences, Inc
$34.38
0.85 (2.54%)
▲
5d:
+4.34%
30d:
+36.32%
90d:
+29.74%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ASMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: ASMB is 12.4% above its trading range ($30.58). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: ASMB is 12.4% above its trading range ($30.58). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: ASMB is currently trading at $34.38, which is considered extended relative to its 30-day fair value range of $24.76 to $30.58.
Technical Outlook: Technically, ASMB is showing sideways momentum. Immediate support is located at $26.23, while resistance sits at $35.62.
Market Sentiment: ASMB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $50.00 (+45.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ASMB is showing sideways momentum. Immediate support is located at $26.23, while resistance sits at $35.62.
Market Sentiment: ASMB scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $50.00 (+45.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$24.76 -
$30.58
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
15.8%
All Signals
- BEARISH: Price significantly overextended (+12.4% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.4% below Wall St target ($50.00)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$24.76 -
$30.58
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$26.24
Resistance Level
$35.62
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.24
Wall Street Target
$50.00
(+45.4%)
Revenue Growth (YoY)
38.9%
Profit Margin
-0.1%
Share & Embed Analysis
Last updated: August 23, 2026 10:58 AM ET
Data refreshes hourly during market hours. Next update: 11:58 AM
Data refreshes hourly during market hours. Next update: 11:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |
